Enlivex Financial Statements From 2010 to 2024

ENLV Stock  USD 1.50  0.18  13.64%   
Enlivex Therapeutics financial statements provide useful quarterly and yearly information to potential Enlivex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enlivex Therapeutics financial statements helps investors assess Enlivex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enlivex Therapeutics' valuation are summarized below:
Market Capitalization
24.6 M
Earnings Share
(1.47)
There are over one hundred nineteen available fundamental signals for Enlivex Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should verify Enlivex Therapeutics' prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 50.2 M in 2024, whereas Enterprise Value is likely to drop slightly above 41.9 M in 2024.

Enlivex Therapeutics Total Revenue

2.28 Million

Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex main balance sheet or income statement drivers, such as Interest Expense of 13.3 K, Total Revenue of 0.0 or Research Development of 18.9 M, as well as many exotic indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.58. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
  
This module can also supplement Enlivex Therapeutics' financial leverage analysis and stock options assessment as well as various Enlivex Therapeutics Technical models . Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.

Enlivex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.6 M36.8 M31.7 M
Pretty Stable
Other Current Liabilities5.1 M4.9 M2.3 M
Slightly volatile
Total Current Liabilities3.6 M6.1 M3.1 M
Slightly volatile
Total Stockholder Equity25.2 M30.1 M27.7 M
Pretty Stable
Accounts Payable1.1 M827 K916.6 K
Pretty Stable
Cash879.7 K926 K8.5 M
Pretty Stable
Short Term Investments27.8 M26.5 M12.1 M
Slightly volatile
Other Current Assets6.3 M6.3 M11.4 M
Slightly volatile
Total Liabilities5.5 M6.7 M3.9 M
Slightly volatile
Intangible Assets350.6 K369 K4.1 M
Slightly volatile
Common Stock2.2 M2.1 M804.9 K
Slightly volatile
Property Plant Equipment18 M17.1 M4.2 M
Slightly volatile
Long Term Debt3.4 M3.6 M4.1 M
Slightly volatile
Good Will19.9 M13.6 M16.4 M
Slightly volatile
Preferred Stock Total Equity10.2 M9.7 M8.1 M
Slightly volatile
Other Liabilities5.1 M4.9 M1.8 M
Slightly volatile
Cash And Short Term Investments23 M27.4 M18.3 M
Slightly volatile
Net Receivables879 K744 K695.5 K
Slightly volatile
Common Stock Total EquityM1.9 M708.2 K
Slightly volatile
Common Stock Shares Outstanding19.5 M18.6 M6.8 M
Slightly volatile
Liabilities And Stockholders Equity31.4 M36.8 M24.9 M
Slightly volatile
Other Stockholder Equity145.9 M138.9 M58.4 M
Slightly volatile
Total Current Assets28.5 M33.8 M22.6 M
Slightly volatile
Property Plant And Equipment Net3.3 M2.6 M2.3 M
Slightly volatile
Property Plant And Equipment Gross22.3 M21.2 M5.1 M
Slightly volatile
Capital Surpluse32.3 M33.4 M38.4 M
Slightly volatile
Net Tangible Assets32.8 M65.4 M21.5 M
Slightly volatile
Net Invested Capital36.8 M65.4 M21.7 M
Slightly volatile
Net Working Capital33.7 M52.6 M19.5 M
Slightly volatile
Capital Stock1.7 M2.4 M1.3 M
Slightly volatile
Short and Long Term Debt Total1.5 MM628.7 K
Slightly volatile
Capital Lease Obligations438.9 K751 K259.5 K
Slightly volatile
Non Current Liabilities Other2.9 M4.8 M1.4 M
Slightly volatile
Short Term Debt427.2 K346 K231.7 K
Slightly volatile

Enlivex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Research Development18.9 M18 M7.8 M
Slightly volatile
Selling General Administrative5.8 K6.1 K4.8 M
Slightly volatile
Other Operating Expenses12.8 M24.9 M10.2 M
Slightly volatile
Total Operating Expenses12.7 M24.1 M10.1 M
Slightly volatile
Selling And Marketing Expenses7.4 MM3.4 M
Slightly volatile
Interest IncomeM960.2 K279.6 K
Slightly volatile
Reconciled Depreciation448.8 K856 K250.2 K
Slightly volatile

Enlivex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities342 K360 K15.6 M
Very volatile
Stock Based Compensation1.9 KK857.8 K
Slightly volatile
End Period Cash Flow879.7 K926 K7.7 M
Slightly volatile
Begin Period Cash Flow52.4 M49.9 M11.4 M
Slightly volatile
Sale Purchase Of Stock10.2 M7.5 M16.5 M
Slightly volatile
Depreciation876.8 K835 K252.8 K
Slightly volatile
Issuance Of Capital Stock342 K360 K8.9 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.0143.8847.7808
Slightly volatile
PTB Ratio1.581.667247
Slightly volatile
Days Sales Outstanding149168183
Slightly volatile
Book Value Per Share1.541.619614.6022
Pretty Stable
Invested Capital0.01090.01150.0196
Slightly volatile
Stock Based Compensation To Revenue0.230.260.2877
Slightly volatile
PB Ratio1.581.667247
Slightly volatile
EV To Sales37.0841.7245.4262
Slightly volatile
Payables Turnover0.791.00970.8558
Slightly volatile
Sales General And Administrative To Revenue1.261.421.5497
Slightly volatile
Research And Ddevelopement To Revenue2.142.412.6198
Slightly volatile
Cash Per Share1.41.47697.9945
Slightly volatile
Capex To Operating Cash Flow0.00950.010.0497
Slightly volatile
Days Payables Outstanding455362453
Slightly volatile
Income Quality0.680.80920.8088
Slightly volatile
Intangibles To Total Assets0.01860.0210.0229
Slightly volatile
Current Ratio5.295.57079.5106
Very volatile
Tangible Book Value Per Share1.541.619614.5991
Pretty Stable
Receivables Turnover1.571.761.9174
Slightly volatile
Graham Number7.177.551849.8211
Pretty Stable
Shareholders Equity Per Share1.541.619614.6022
Pretty Stable
Debt To Equity0.01090.01150.0196
Slightly volatile
Graham Net Net1.061.11376.5479
Slightly volatile
Revenue Per Share0.140.160.1698
Slightly volatile
Interest Debt Per Share0.01840.01940.0719
Slightly volatile
Debt To Assets0.00890.00940.0152
Slightly volatile
Price Book Value Ratio1.581.667247
Slightly volatile
Days Of Payables Outstanding455362453
Slightly volatile
Ebt Per Ebit0.821.16611.0032
Very volatile
Company Equity Multiplier1.381.22431.3729
Slightly volatile
Long Term Debt To Capitalization0.00.00.0086
Slightly volatile
Total Debt To Capitalization0.01080.01140.0187
Slightly volatile
Debt Equity Ratio0.01090.01150.0196
Slightly volatile
Quick Ratio4.34.52628.2018
Very volatile
Dividend Paid And Capex Coverage Ratio19999.6737221
Slightly volatile
Net Income Per E B T0.831.231.0304
Pretty Stable
Cash Ratio0.150.15285.8017
Pretty Stable
Days Of Sales Outstanding149168183
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.861.011.0397
Pretty Stable
Price To Book Ratio1.581.667247
Slightly volatile
Fixed Asset Turnover0.850.961.0428
Slightly volatile
Capital Expenditure Coverage Ratio19999.6737221
Slightly volatile
Debt Ratio0.00890.00940.0152
Slightly volatile
Price Sales Ratio39.0143.8847.7808
Slightly volatile
Asset Turnover0.04510.05080.0553
Slightly volatile
Gross Profit Margin0.70.790.8571
Slightly volatile
Price Fair Value1.581.667247
Slightly volatile

Enlivex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap50.2 M50.2 M55.7 M
Pretty Stable
Enterprise Value41.9 M50.3 M46.9 M
Pretty Stable

Enlivex Fundamental Market Drivers

Cash And Short Term Investments27.4 M

Enlivex Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
21st of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enlivex Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Enlivex Therapeutics income statement, its balance sheet, and the statement of cash flows. Enlivex Therapeutics investors use historical funamental indicators, such as Enlivex Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Enlivex Therapeutics investors may use each financial statement separately, they are all related. The changes in Enlivex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enlivex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Enlivex Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue 0.00  0.00 
Cost Of Revenue835 K793.2 K
Stock Based Compensation To Revenue 0.26  0.23 
Sales General And Administrative To Revenue 1.42  1.26 
Research And Ddevelopement To Revenue 2.41  2.14 
Capex To Revenue(0.40)(0.42)
Revenue Per Share 0.16  0.14 
Ebit Per Revenue(3.87)(4.06)

Pair Trading with Enlivex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:
Check out the analysis of Enlivex Therapeutics Correlation against competitors.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Enlivex Stock analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.47)
Return On Assets
(0.30)
Return On Equity
(0.67)
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.